• Climb Bio highlighted completed Phase 1 results for subcutaneous budoprutug in healthy volunteers, showing B-cell depletion comparable to intravenous dosing, supporting a planned multiple-dose study in autoimmune patients.
• Initial readouts from ongoing budoprutug trials are scheduled for 2026, led by low-dose cohort data in immune thrombocytopenia expected in June, followed by early primary membranous nephropathy signals in Q4.
• CLYM116 modeling and initial Phase 1 safety data are set for presentation at ERA 2026 in June, with initial Phase 1 PK/PD data expected mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-210295), on May 07, 2026, and is solely responsible for the information contained therein.